source
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.Fierce Biotech · 17h ago↗ source
- Boehringer Ingelheim pauses Phase 1 study of oral candidate BI 3031185 after safety eventBoehringer Ingelheim has placed a Phase 1 study of its oral candidate BI 3031185 on hold after a safety event was identified. The trial, run in Japan with healthy volunteers, was assessing tolerab…